Ocular Therapeutix (NSDQ:OCUL) said it expects to reap $66 million from a follow-on offering of 4 million shares, after underwriting expenses, as it pushes forward with its drug-device combination for treating post-surgical ocular pain. The Bedford, Mass.-based company last week priced the offering at $22 per share for both the 3.2 million shares it’s floating and the […]
oculartherapeutix
Nevro, Intersect ENT, Ocular Therapeutix announce follow-on offerings
A trio of medical device companies that went public last year are planning follow-on offerings to raise more cash. Nevro Corp. (NYSE:NVRO), Intersect ENT (NSDQ:XENT) and Ocular Therapeutix (NSDQ:OCUL) all revealed plans for the flotations this week. Menlo Park, Calif.-based Nevro priced its 1.8-million-share offering yesterday at $51 per share, saying stockholders would put up another […]
Ocular Therapeutix presses ahead with eye drug-device combo
Ocular Therapeutix plunges on missed endpoint in eye drug trial
Ocular Therapeutix eye drug meets goal in late-stage study
Ocular Therapeutix launches dry-eye trial
2014: The year of the medtech IPO | Medtech Wall Street news for the week of December 15, 2014
Year in review: 2014 was the year of the medtech IPO
The importance of being scrappy: Tips from med tech entrepreneur Amar Sawhney
Ocular Therapeutix set to start 2 Phase III studies for eye-duct plug
Ocular Therapeutix IPO reaches $75M with over-allotment
Bedford, Mass.-based Ocular Therapeutix (NSDQ:OCUL) raised $74.8 million though its initial public offering after underwriters fully exercised an over-allotment option to snag additional shares.